RxDoctor Payments Data

James Walton, MD

Family Medicine · Augusta, GANPI 1578724779

Payments from drug & device makers

$4,387in general payments, 2019–2025

Across 281 payments — averaging $15.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$883
  • Novo Nordisk$694
  • Lilly USA, LLC$420
  • Pfizer$367
  • AstraZeneca$348
  • Abbott$248
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$4,381100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,387 in reported general payments places this provider in the 80th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$82,499
Medicare patients
210
Services billed
1,192

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide88$106,791
EliquisApixaban79$75,002
JardianceEmpagliflozin46$50,577
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$40,243
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$26,980
MounjaroTirzepatide23$23,472
JanuviaSitagliptin Phosphate16$23,282
FarxigaDapagliflozin Propanediol26$23,100
RybelsusSemaglutide13$19,594
Spiriva RespimatTiotropium Bromide18$11,232
ShingrixVaricella-Zoster Ge/As01b/Pf49$10,927
Spiriva HandihalerTiotropium Bromide19$9,886
MyrbetriqMirabegron12$6,959
MovantikNaloxegol Oxalate12$5,958
SymbicortBudesonide/Formoterol Fumarate21$5,934

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$694$126,385101 claims
PfizerEliquis$367$75,00279 claims
Boehringer IngelheimJardiance, Spiriva Respimat$190$61,80964 claims
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$348$56,01373 claims
GSKTrelegy Ellipta, Shingrix$48$51,17096 claims
Lilly USA, LLCMounjaro$420$23,47223 claims
MerckJanuvia$14$23,28216 claims
AbbVieSynthroid$883$1,70817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →